Understanding Complex Product Characterization Analysis Session 2a
Exploring Complex Product Characterization Analysis Session 2a reveals several interesting facts. A presentation and panel discuss potential gaps in
Key Takeaways about Complex Product Characterization Analysis Session 2a
- Asif Rasheed from the Office of Pharmaceutical Quality discusses common issues and challenges for
- Myong-Jin Kim from CDER's Office of Generic Drugs discusses non-
- FDA discusses additional topics in
- FDA discusses topics in
- Yiwei Li from CDER's Office of Pharmaceutical Quality shares a case study, an introduction to Iron Colloid Drug
Detailed Analysis of Complex Product Characterization Analysis Session 2a
A presentation and panel discuss new analytical methods that are promising for generic drug development, screening, and ... A presentation and panel assess analytical methods currently considered most useful and how to better develop these ... In this audiocast, we discover the cutting-edge analytical tools that are revolutionizing the
In the race to bring a new biotherapeutic to market, unexpected obstacles can slow you down or even knock you back a few steps.
Stay tuned for more updates related to Complex Product Characterization Analysis Session 2a.
